Among the top stories in cardiology last week week was a CDC data brief that indicated heart disease remained the leading cause of death in the United States and the FDA recall involving temporary pacing leads designated as class 1.
Other popular stories included findings that sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists significantly improved CV outcomes, an in-depth look at CV benefits from prescription fish oil, and data that showed bempedoic acid may be a safe and effective therapy in lowering LDL levels in certain patients. – by Janel Miller
CDC: Heart disease, cancer leading causes of death in 2017
The 10 leading causes of death in the United States in 2017 were the same as 2016, with heart disease and cancer topping the list, according to a National Center for Health Statistics Data Brief published by the CDC. Read more.
FDA designates recall of temporary pacing leads as class 1
The FDA has designated the product recall of temporary bipolar pacing leads as class 1, the most serious kind. The recall affects 4,778 pacing leads manufactured and distributed between Dec. 21, 2011, and May 17, 2018. Read more.
SGLT2 inhibitors, GLP-1 agonists reduce CV risk in type 2 diabetes
Recent studies have shown that sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists significantly improve CV outcomes, according to an American College of Cardiology expert consensus decision pathway published in the Journal of the American College of Cardiology. Read more.
VIDEO: A deep dive into CV benefits of prescription fish oil
CHICAGO — Deepak L. Bhatt, MD, MPH, highlighted results of the REDUCE-IT trial, which found that icosapent ethyl was superior to placebo for reducing risk for ischemic events, in this video exclusive. Watch video.
Bempedoic acid lowers LDL in statin-intolerant patients
CHICAGO — For patients with hypercholesterolemia who are intolerant to statins, bempedoic acid may be a safe and effective therapy to aid in lowering LDL levels, according to findings presented at the American Heart Association Scientific Sessions. Read more.